Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2009
11/19/2009WO2009036082A3 Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
11/19/2009WO2009015447A3 Polyacetal-carboxylic acids in the treatment of cancer and auto-immune disorders
11/19/2009WO2008131940A3 Combination of immunological agent and sensitizing agent for the treatment of cancer
11/19/2009WO2008119567A8 Cross-species-specific cd3-epsilon binding domain
11/19/2009WO2008093166A3 Targeting macrophages through sialoadhesin
11/19/2009US20090286986 Isoindole-imide compounds, compositions, and uses thereof
11/19/2009US20090286870 Cancer Treatment Using FTS and 2-Deoxyglucose
11/19/2009US20090286868 2-Amino-2-oxoethyl trans-3-[5-(naphth-1-yl)-1,3-dioxan-2-yl]propyl carbamate; reacting the phenylcarbonate with 2-aminodioxane; fatty acid amido hydrolase (FAAH) inhibitors; analgesics; nervous system disorders; gastrointestinal disorders,; to name just a few
11/19/2009US20090286865 Potentiator of antitumoral agents in the treatment of cancer
11/19/2009US20090286859 POTENT LNA OLIGONUCLEOTIDES FOR THE INHIBITION OF HIF-1a EXPRESSION
11/19/2009US20090286858 Assays for modulators of asparaginyl hydroxylase
11/19/2009US20090286855 Interleukin-18 mutants, their production and use
11/19/2009US20090286854 Aptamers directed to muci
11/19/2009US20090286853 Modified oligonucleotides for telomerase inhibition
11/19/2009US20090286849 Modulation of insulin like growth factor i receptor expression
11/19/2009US20090286841 Certain chemical entities, compositions, and methods
11/19/2009US20090286840 Polo-like kinase inhibitors such as 5-(5-Amino-2H-pyrazol-3-yl)-3-[1-(2-chloro-phenyl)-ethoxy]-thiophene-2-carboxylic acid amide, useful for treating or preventing autoimmune, inflammatory, proliferative or hyperproliferative disease, a neurodegenerative disease, or an immunologically-mediated disease
11/19/2009US20090286838 Treatment for cancer
11/19/2009US20090286837 Oxadiazole compounds as urokinase inhibitors
11/19/2009US20090286824 Pyridine Classical Cannabinoid Compounds and Related Methods of Use
11/19/2009US20090286823 CCR1 Inhibitors useful for the treatment of multiple myeloma and other disorders
11/19/2009US20090286822 Treatment of psoriasis and of other skin disorders associated with inhibition of differentiation of epidermal cells
11/19/2009US20090286821 Inhibitors of tyrosine kinases
11/19/2009US20090286818 Pyridine Non-Classical Cannabinoid Compounds and Related Methods of Use
11/19/2009US20090286817 Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester
11/19/2009US20090286815 Pyrimidine Classical Cannabinoid Compounds and Related Methods of Use
11/19/2009US20090286810 Pyrimidine Non-Classical Cannabinoid Compounds and Related Methods of Use
11/19/2009US20090286803 Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
11/19/2009US20090286796 Compounds exhibiting type X sPLA2 inhibiting effect
11/19/2009US20090286793 Pde4b inhibitors and uses therefor
11/19/2009US20090286786 Compounds having a 4-pyridylalkylthio group as a substituent
11/19/2009US20090286785 Pyrimidine Derivatives
11/19/2009US20090286782 Compounds and methods for kinase modulation, and indications therefor
11/19/2009US20090286770 Use of Staurosporine Derivatives for the Treatment of Multiple Myeloma
11/19/2009US20090286760 Novel Compositions and Methods for Treating Hyperproliferative Diseases
11/19/2009US20090286755 Potentiator of radiation therapy
11/19/2009US20090286752 Oral formulations of cytidine analogs and methods of use thereof
11/19/2009US20090286742 polypeptides comprising amino acid sequences corresponding to, similar to or homologous to part of the amino acid sequence of neural thread proteins, used for treating unwanted cellular proliferations such as benign prostatatic hyperplasia, cancer, unwanted facial hair, warts and fatty tissues
11/19/2009US20090286738 Gene Regulation
11/19/2009US20090286737 Erbb interface peptidomimetics and methods of use thereof
11/19/2009US20090286736 using polypeptide comprising a membrane translocation domain and a NF- kappa B Essential Modulator (NEMO) binding sequence; comprising a NEMO binding domain (NBD)
11/19/2009US20090286729 Epidermal Growth Factor Receptor Antagonists and Methods of Use
11/19/2009US20090286720 Pharmaceutical composition for the diagnosis, prevention or treatment of a tumoral pathology comprising an agent modulating the polymerization state of actin
11/19/2009US20090286713 Collagen Receptor I-Domain Binding Modulators
11/19/2009US20090286316 Nucleic acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer
11/19/2009US20090286313 Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
11/19/2009US20090286265 Cripto Blocking Antibodies And Uses Thereof
11/19/2009US20090285919 Rice Bran Extracts for Inflammation and Methods of Use Thereof
11/19/2009US20090285878 Compositions and methods for stabilizing liposomal drug formulations
11/19/2009US20090285864 Therapeutic formulation
11/19/2009US20090285841 Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
11/19/2009US20090285833 Clostridium botulinum c3 exotransferase compositions and methods for treating tumour spreading
11/19/2009US20090285832 Methods for treating sunitinib-resistant carcinoma and related biomarkers
11/19/2009US20090285831 Immunointeractive molecules
11/19/2009US20090285828 Anti-PECAM Therapy for Metastasis Suppression
11/19/2009US20090285824 immunoglobulins; humanizing; chimera; fragments; complementary determining regions; breast cancer
11/19/2009US20090285822 Prevention and treatment of amyloidogenic disease
11/19/2009US20090285818 Cripto Blocking Antibodies and Uses Thereof
11/19/2009US20090285817 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene
11/19/2009US20090285816 Albumin Fusion Proteins
11/19/2009US20090285814 CD 40 Binding Molecules and CTL Pepetides for Treating Tumors
11/19/2009US20090285810 Humanized anti-tgf-beta antibodies
11/19/2009US20090285809 Prevention and treatment of amyloidogenic diseases
11/19/2009US20090285802 Highly concentrated stabilized igm solution
11/19/2009US20090285796 Mutant jak3 kinase in human leukemia
11/19/2009US20090285792 Compositions and methods for treatment of neovascular diseases
11/19/2009US20090285783 Methods and compositions for cancer therapy using a novel adenovirus
11/19/2009US20090285778 Use of interleukin-19 to treat cervical cancer
11/19/2009US20090285772 Quinoline derivatives for modulating dna methylation
11/19/2009US20090285760 Method for detecting cancer using icg fluorescence method
11/19/2009US20090285759 Drug, drug guidance system, magnetic detection system, and drug design method
11/19/2009US20090285757 Methods of targeting cells for diagnosis and therapy
11/19/2009US20090285753 Novel haptotactic peptides
11/19/2009US20090285750 Agent, composition and method
11/19/2009DE102008016275A1 Composition, useful e.g. transfection comprises a non-viral gene delivery system containing e.g. cationic lipid, and an agent for partial suppression and/or activation of innate intracellular and/or intercellular immune defense
11/19/2009CA2724525A1 Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
11/19/2009CA2724413A1 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
11/19/2009CA2724409A1 Anti-cxcr4 antibodies
11/19/2009CA2724384A1 Treatment of metastatic tumors
11/19/2009CA2724325A1 Combination therapy with an antitumor alkaloid
11/19/2009CA2724262A1 Pyrrolopyridines as kinase inhibitors
11/19/2009CA2724246A1 Anticancer combination therapy including triciribine
11/19/2009CA2724215A1 Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs
11/19/2009CA2724208A1 Amino acid sequences directed against cxcr4 and other gpcrs and compounds comprising the same
11/19/2009CA2724206A1 Multiple myeloma treatments
11/19/2009CA2724077A1 Amide compound
11/19/2009CA2724071A1 Plasmacytoid dendritic cell line used in active or adoptive cell therapy
11/19/2009CA2724055A1 Glucocorticoid receptor agonist comprising 2,2,4-trimethyl-6-phenyl-1,2 -dihydroquinoline derivatives having substituted oxy group
11/19/2009CA2724020A1 Substituted quinazolines and their uses for myeoloprolific and thrombotic diseases
11/19/2009CA2724003A1 Novel n-(2-amino-phenyl)-acrylamides
11/19/2009CA2723989A1 Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
11/19/2009CA2723973A1 Anti-fn14 antibodies and uses thereof
11/19/2009CA2723860A1 Plant extract and its therapeutic use
11/19/2009CA2723768A1 Novel uses of d-mannopyranose derivatives
11/19/2009CA2723767A1 Novel uses of d-mannopyranose derivatives activating angiogenesis
11/19/2009CA2723617A1 Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
11/19/2009CA2723465A1 Proteasome inhibitors
11/19/2009CA2722418A1 Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
11/18/2009EP2119792A1 Novel macrolide compound
11/18/2009EP2119784A2 Method and compositions for cellular reprogramming
1 ... 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 ... 2211